DelveInsight’s Dystrophic Epidermolysis Bullosa epidemiology forecast report provides a comprehensive understanding of Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology, and Dystrophic Epidermolysis Bullosa trends in the 7MM.
Key Takeaways from the Dystrophic Epidermolysis Bullosa Epidemiology Forecast Report
-
As per DelveInsight’s Dystrophic Epidermolysis Bullosa epidemiology insights, the total diagnosed prevalent cases were 40,238 in the 7MM in 2020.
-
As per the estimates, out of all the DEB diagnosed prevalent cases in the US, 52.5% of cases were of Dominant Dystrophic Epidermolysis Bullosa (DDEB).
-
Among the EU5, Germany had the highest DEB diagnosed prevalent cases while France had the lowest in 200.
-
In Japan, the DEB diagnosed prevalent cases was over 1 thousand in 2020.
To learn more about the symptoms, diagnosis, and treatment, request for sample @ Dystrophic Epidermolysis Bullosa Treatment
Dystrophic Epidermolysis Bullosa: Overview
Dystrophic Epidermolysis Bullosa (DEB) is one of the most common types of EB. Mutations in the COL7A1 gene cause it, and it can be inherited in an autosomal dominant or autosomal recessive manner. Mutations in COL7A1, which encodes type VII collagen, a major component of anchoring fibrils, cause all DEB subtypes.
Dystrophic Epidermolysis Bullosa Epidemiology Segmentation
The Dystrophic Epidermolysis Bullosa report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
-
Epidermolysis Bullosa Total Diagnosed Prevalent Population
-
Dystrophic Epidermolysis Bullosa Total Diagnosed Prevalent Population
-
Dystrophic Epidermolysis Bullosa Subtype-Specific Diagnosed Prevalent Population
Get a detailed analysis of epidemiology segmentation @ Dystrophic Epidermolysis Bullosa Epidemiology
Table of Contents
|
1. |
Key Insights |
|
2. |
Executive Summary |
|
3. |
Dystrophic Epidermolysis Bullosa (DEB) Epidemiology Overview at a Glance |
|
4. |
Dystrophic Epidermolysis Bullosa (DEB): Disease Background and Overview |
|
5. |
Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population |
|
6. |
Country Wise Epidemiology of Dystrophic Epidermolysis Bullosa |
|
7. |
Patient Journey |
|
8. |
KOL Views |
|
9. |
Appendix |
|
10. |
DelveInsight Capabilities |
|
11. |
Disclaimer |
|
12. |
About DelveInsight |
Get in touch with our business executive for Healthcare Due Diligence Services
Related Reports
Epidermolysis Bullosa Epidemiology Forecast
“DelveInsight’s ‘Epidermolysis Bullosa (EB)-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the EB, historical and forecasted epidemiology as well as the EB trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/